Pfizer's 2024 Outlook: Is PFE Stock Poised for a Major Rebound?

Post-pandemic, the global bio-pharmaceutical sector, often overlooked, presents undervalued opportunities, notably in blue-chip stocks like Pfizer (NYSE:PFE). Following a 42% correction in the past year, PFE stock, with a 5.84% dividend yield, appears promising for 2024. The company anticipates $60 billion in revenue, signaling 9% year-on-year growth, supported by a compelling product pipeline.Here are some more reasons why investing in PFE stock will bring you to ultimate highs in 2024.The Excellent Bull C ...